Electrome Provides LymeCure Research Collaboration Milestone Update

Electrome Corporation today provided a milestone update on the LymeCure research collaboration with Tulane University. The collaboration is moving toward structured mouse model evaluation, with promising early signals from the in vitro phase that the team has determined warrant the next stage of work. The collaboration remains research stage. No clinical claim is being made and no clinical access timeline is being communicated.

Update scope

The mouse model phase is structured to evaluate whether specific bioelectric exposures, applied in defined patterns, produce measurable changes in markers relevant to Lyme dynamics. Endpoints are biological, not clinical.

Forward looking statements

This release includes forward looking statements regarding research progress. Research outcomes are inherently uncertain and may differ from expectations.

About LymeCure

LymeCure is the research collaboration between Electrome Corporation and the Tulane National Primate Research Center exploring whether bioelectric inputs may have a role to play in chronic and persistent infection science, with an initial focus on Lyme disease. The work is in defined research stages and has not produced a clinical claim. The collaboration follows the rigorous methodology that this kind of work requires, and the timeline reflects the realities of carefully conducted preclinical research.

What the research stage means

Research stage means the work is producing data that the team uses to design subsequent studies. It does not mean the work is producing therapy that patients can use. The Electrome platform's clinical claims remain limited to the FDA cleared use of the underlying pulsed shortwave therapy device for musculoskeletal pain and edema. The LymeCure program is a separate research effort, governed under research ethics and methodology, and it is described as such consistently across all company communications.

About Electrome Corporation

Electrome Corporation operates the bioelectric medicine platform behind PAINKILLER and supports a research portfolio that includes the LymeCure collaboration. The company's stated posture is to keep research clearly separated from cleared clinical claims, and to communicate research progress with the candor that the rigor of the work requires.